INDV PE Ratio & Valuation, Is INDV Overvalued

Historical Valuation

Indivior Pharmaceuticals, Inc (INDV) is now in the Fair zone, suggesting that its current forward PE ratio of 12.72 is considered Fairly compared with the five-year average of 12.61. The fair price of Indivior Pharmaceuticals, Inc (INDV) is between 30.40 to 43.90 according to relative valuation method.

Relative Value

Fair Zone

30.40-43.90

Current Price：31.65

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Indivior Pharmaceuticals, Inc (INDV) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Indivior Pharmaceuticals, Inc (INDV) has a current Price-to-Book (P/B) ratio of -21.58. Compared to its 3-year average P/B ratio of 13.31, the current P/B ratio is approximately -262.07% higher. Relative to its 5-year average P/B ratio of 14.44, the current P/B ratio is about -249.41% higher. Indivior Pharmaceuticals, Inc (INDV) has a Forward Free Cash Flow (FCF) yield of approximately 2.67%. Compared to its 3-year average FCF yield of -5.40%, the current FCF yield is approximately -149.38% lower. Relative to its 5-year average FCF yield of -0.80%, the current FCF yield is about -435.39% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for INDV competitors is 24.95, providing a benchmark for relative valuation. Indivior Pharmaceuticals, Inc Corp (INDV.O) exhibits a P/S ratio of 3.88, which is -84.43% above the industry average. Given its robust revenue growth of 2.28%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of INDV increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of INDV in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is INDV currently overvalued or undervalued?

What is Indivior Pharmaceuticals, Inc (INDV) fair value?

INDV's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Indivior Pharmaceuticals, Inc (INDV) is between 30.40 to 43.90 according to relative valuation method.

How does INDV's valuation metrics compare to the industry average?

The average P/S ratio for INDV's competitors is 24.95, providing a benchmark for relative valuation. Indivior Pharmaceuticals, Inc Corp (INDV) exhibits a P/S ratio of 3.88, which is -84.43% above the industry average. Given its robust revenue growth of 2.28%, this premium appears unsustainable.

What is the current P/B ratio for Indivior Pharmaceuticals, Inc (INDV) as of Mar 17 2026?

As of Mar 17 2026, Indivior Pharmaceuticals, Inc (INDV) has a P/B ratio of -21.58. This indicates that the market values INDV at -21.58 times its book value.

What is the current FCF Yield for Indivior Pharmaceuticals, Inc (INDV) as of Mar 17 2026?

As of Mar 17 2026, Indivior Pharmaceuticals, Inc (INDV) has a FCF Yield of 2.67%. This means that for every dollar of Indivior Pharmaceuticals, Inc's market capitalization, the company generates 2.67 cents in free cash flow.

What is the current Forward P/E ratio for Indivior Pharmaceuticals, Inc (INDV) as of Mar 17 2026?

As of Mar 17 2026, Indivior Pharmaceuticals, Inc (INDV) has a Forward P/E ratio of 12.72. This means the market is willing to pay $12.72 for every dollar of Indivior Pharmaceuticals, Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Indivior Pharmaceuticals, Inc (INDV) as of Mar 17 2026?

As of Mar 17 2026, Indivior Pharmaceuticals, Inc (INDV) has a Forward P/S ratio of 3.88. This means the market is valuing INDV at $3.88 for every dollar of expected revenue over the next 12 months.

INDV Valuation